HDAC inhibitors: double edge sword for TRAIL cancer therapy?
Fulda
Simone
S
University Children's Hospital, Ulm, Germany. simone.fulda@medizin.uni-ulm.de
Debatin
Klaus-Michael
KM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics / Q000494:pharmacology*; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000494:pharmacology*
D051017:Apoptosis Regulatory Proteins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D008562:Membrane Glycoproteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha